This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"Coordinated signaling between HER-family receptors and c-Met has been demonstrated to drive breast cancer in some patients. Although combination therapies targeting HER and c-Met can be very effective in some of these patients, no clinical data has supported an approval for this drug combination in breast cancer. In a recent study, researchers examined the ability of a new clinical test to identify potentially responsive patients. The test, called the CELsignia Multi-Pathway Signaling Function Test, uses an impedance biosensor loaded with a patient’s live tumor cells to quantify cell signaling responses in real time. Using this test, the researchers identified patients whose HER2-negative breast tumors had hyperactive coordinated HER1, HER2, HER3/4, and c-Met signaling, despite having normal expression levels of these receptors on their tumor cells. These results indicated that the identified patients might be responsive to HER-/c-Met-targeting combination therapy..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
- Subject:
- Biology
- Life Science
- Material Type:
- Diagram/Illustration
- Reading
- Provider:
- Research Square
- Provider Set:
- Video Bytes
- Date Added:
- 05/17/2022